Atrasentan: The first endothelin receptor antagonist for hormone-refractory prostate cancer

European Urology, Supplement

Volumn 2, Issue 3, 2003, Pages 20-27

  Schulman, Claude ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

ABT 627; Atrasentan; Bone metastases: Phase II; Disease progression; Endothelin; Hormone refractory prostate cancer; M96 594; Quality of life

Indexed keywords

ATRASENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

APOPTOSIS; ASTHENIA; ATTENUATION; BONE METASTASIS; BONE REMODELING; CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG TOLERABILITY; HEADACHE; HORMONE RESISTANCE; HUMAN; LONG TERM CARE; MITOSIS INHIBITION; NONHUMAN; PERIPHERAL EDEMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; RHINITIS; TREATMENT FAILURE;

EID: 0037345814     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00205-1     Document Type: Review

References (29)

1. Bagnato A, Salani D, Di Castro V, Wu-Wong J, Tecce R, Nicotra M, et al. Expression of endothelin-1 and endothelin-A receptor in ovarian carcinoma: evidence for an autocrine role in tumour growth. Cancer Res 1999;59(3):720-7.
2. Venuti A, Salani D, Manni V, Poggiali F, Bagnato A. Expression of endothelin-1 and endothelin-A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 2000;14(14):2277-83.
3. Salani D, Di Castron V, Nicotra MR, Rosanò L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000;157(5):1537-47.
4. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944-9.
5. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova S, et al. Endothelin-1 production and decreased endothelin-B receptor expression in advanced prostate cancer. Cancer Res 1996;56(4):663-8.
6. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44(1):77-81.
7. Usmani BA, Shen R, Janeczko M, Papandreou CN, Lee WH, Nelson WG, et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000;6(5):1664-70.
8. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001;165(3):1033-6.
9. Opgenorth TJ, Adler AL, Calzadilla SV, Chiou WJ, Dayton BD, Dixon DB, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996;276(2):473-81.
10. Nelson JB. Endothelin receptor antagonists in the treatment of prostate cancer. Prostate 2001;49(2):91-2.
11. Chiou WJ, Wessale JL, Von Geldern T, Opgenorth TJ, Wu-Wong JR. Irreversible endothelin-1 binding does not prohibit ABT-627 from reversing endothelin-1-induced effects. J Cardiovasc Pharmacol 2000;36(Suppl 1):S48-52.
12. Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, et al. New bone formation in an osteoblastic tumour model is increased by endothelin-1 over expression and decreased by endothelin-A receptor blockade. Urology 1999;53(5):1063-9.
13. Guise T, Grubbs BG, Cui Y, Wu-Wong JR, Wessale J, Padely RJ, et al. Endothelin A receptor blockade inhibits osteoblastic metastases. J Clin Oncol 2001;(Suppl) [Abstract 331].
14. Carducci M, Nelson JB, Padley RJ, Janus R, Hippensteel R. The endothelin-A receptor antagonist atrasentan (ABT-627) reduces skeletal remodelling activity in men with advanced, hormone refractory prostate cancer. J Clin Oncol 2001;(Suppl) [Abstract 6941.
15. Schulman C, Abrahamsson P, Humerickhouse R, Weinberg MA, Schmitt J, Nabulsi A. Metastatic hormone refractory prostate cancer: a randomized phase II study of the endothelin-A receptor antagonist atrasentan. Eur Urol Suppl 2002;1(1):157 [Abstract 105].
16. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, et al. Effect of endothelin-A receptor blockade with atrasentan on tumour progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679-89.
17. Schulman C, Nelson JB, Weinberg MA, Schmitt JL, Nabulski AA. Atrasentan delayed PSA progression in a phase II trial of men with hormone-refractory prostate cancer. J Urol 2002;167(Suppl):176 [Abstract 705].
18. Carducci MA, Nelson JB, Humerickhouse R, Weinberg M, Schmitt J, Nabulsi A. Effects of atrasentan on progression and survival in men with hormone-refractory prostate cancer: follow-up to study M96-594. J Clin Oncol 2002;(Suppl) [Abstract 708].
19. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999;17(8):2506-13.
20. Takuwa Y, Maski T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvarie. Biochem Biophys Res Commun 1990;170(3):998-1005.
21. Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman A, Wu-Wong JR, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000;83(3):360-5.
22. Nelson JB, Carducci MA, Padley RJ, Janus T, Humerickhouse R, Hippensteel R. The endothelin-A antagonist atrasentan (ABT-627) reduces skeletal remodelling activity in men with advanced, hormone refractory prostate cancer. J Clin Oncol 2001;(Suppl) [Abstract 12].
23. Carducci MA, Bowling M, Rogers T, Leahy T, Moyse D, Janus T, et al. ABT-627, an endothelin-receptor antagonist for refractory adenocarcinomas: phase I and pharmacologic evaluation. J Clin Oncol 1999;(Suppl) [Abstract 625].
24. Zonnenberg B, Anbaum R, Kronemeier R, Yang F, Samra E, Janus TJ, et al. Results of an initial phase I dose-escalation study of the endothelin-A receptor antagonist ABT-627 in patients with hormone refractory prostate cancer. J Clin Oncol 1999;(Suppl) [Abstract 626].
25. Dutta S, Samara E, Lam W, Granneman GR, Leese PT, Padley RJ. Multiple dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Clin Drug Invest 2001;21:129-36.
26. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20(8):2171-80.
27. Verhaar MC, Grahn AY, Van Weerdt AWM, Honing MLH, Morrison PJ, Yang YP, et al. Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol 2000;49(6):562-73.
28. Ryan CW, Janus TJ, Vogelzand NJ, Vokes EE, Kindler HL, Dutta S, et al. A phase I study of men and women with refractory malignancies given daily dosing of an endothelin receptor antagonist. J Clin Oncol 2000;(Suppl) [Abstract 783].
29. Singh A, Padley RJ, Ashraf T. The selective endothelin-A receptor antagonist atrasentan improves quality of life adjusted time to progression (QATTP) in hormone refractory prostate cancer patients. J Clin Oncol 2001;(Suppl) [Abstract 1567].